SG11202009213TA - Separation of vwf and vwf propeptide by chromatographic methods - Google Patents

Separation of vwf and vwf propeptide by chromatographic methods

Info

Publication number
SG11202009213TA
SG11202009213TA SG11202009213TA SG11202009213TA SG11202009213TA SG 11202009213T A SG11202009213T A SG 11202009213TA SG 11202009213T A SG11202009213T A SG 11202009213TA SG 11202009213T A SG11202009213T A SG 11202009213TA SG 11202009213T A SG11202009213T A SG 11202009213TA
Authority
SG
Singapore
Prior art keywords
vwf
separation
propeptide
chromatographic methods
chromatographic
Prior art date
Application number
SG11202009213TA
Other languages
English (en)
Inventor
Christian Fiedler
Meinhard Hasslacher
Christa Mayer
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of SG11202009213TA publication Critical patent/SG11202009213TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202009213TA 2018-03-21 2019-03-20 Separation of vwf and vwf propeptide by chromatographic methods SG11202009213TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646109P 2018-03-21 2018-03-21
PCT/US2019/023269 WO2019183290A1 (en) 2018-03-21 2019-03-20 Separation of vwf and vwf propeptide by chromatographic methods

Publications (1)

Publication Number Publication Date
SG11202009213TA true SG11202009213TA (en) 2020-10-29

Family

ID=66223800

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009213TA SG11202009213TA (en) 2018-03-21 2019-03-20 Separation of vwf and vwf propeptide by chromatographic methods

Country Status (14)

Country Link
US (2) US10934340B2 (zh)
EP (1) EP3768697A1 (zh)
JP (2) JP2021519280A (zh)
KR (1) KR20200144547A (zh)
CN (1) CN112533940A (zh)
AU (1) AU2019240135A1 (zh)
BR (1) BR112020019057A2 (zh)
CA (1) CA3094644A1 (zh)
CO (1) CO2020013056A2 (zh)
EA (1) EA202092223A1 (zh)
IL (1) IL277464A (zh)
MX (1) MX2020009788A (zh)
SG (1) SG11202009213TA (zh)
WO (1) WO2019183290A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN115698245A (zh) * 2020-01-27 2023-02-03 百时美施贵宝公司 等电聚焦样品基质

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
CA2094259A1 (en) * 1990-10-17 1992-04-18 Zaverio M. Ruggeri Therapeutic fragments of von willebrand factor
US6190609B1 (en) 1996-11-19 2001-02-20 Baxter International Inc. Methods and apparatus for inactivating contaminants in biological fluid
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP5022231B2 (ja) 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
EP1974014B1 (en) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptide-free cell culture media
US7559509B1 (en) 2007-02-12 2009-07-14 Thomas C. Taylor Large cryogenic tank logistics for in-space vehicles
CN101679496B (zh) * 2007-05-18 2013-03-13 巴克斯特国际公司 用于由vwf前肽制备成熟vwf的方法
CN105816858A (zh) * 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
CN102387784B (zh) 2008-10-21 2014-04-02 巴克斯特国际公司 冻干的重组vwf配方
MX2012002129A (es) 2009-08-20 2012-06-08 Baxter Int Purificacion del factor de von willebrand (vwf) para remocion incrementada de virus envueltos sin lipido.
ES2968448T3 (es) * 2009-12-18 2024-05-09 Csl Ltd Procedimiento de purificación de polipéptidos
ES2761692T5 (es) 2010-07-08 2023-07-05 Takeda Pharmaceuticals Co Método de producción de vWF recombinante de alto peso molecular en cultivo celular
CN105524162B (zh) 2010-12-15 2021-04-27 巴克斯特国际公司 使用改进的溶剂-清洁剂方法进行病毒灭活
HUE039317T2 (hu) * 2011-06-10 2018-12-28 Baxalta GmbH Koagulációs betegség kezelése rekombináns VWF adagolásával
JP6778111B2 (ja) * 2014-01-20 2020-10-28 オクタファルマ・アーゲー ＦＶＩＩＩ：Ｃ／ＦＶＩＩＩ：Ａｇの改良された比を有する第ＶＩＩＩ因子を製造するための方法
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도

Also Published As

Publication number Publication date
US20190382467A1 (en) 2019-12-19
BR112020019057A2 (pt) 2020-12-29
CO2020013056A2 (es) 2020-10-30
EA202092223A1 (ru) 2021-02-10
US20220041693A1 (en) 2022-02-10
AU2019240135A1 (en) 2020-10-22
MX2020009788A (es) 2020-12-09
EP3768697A1 (en) 2021-01-27
US10934340B2 (en) 2021-03-02
CA3094644A1 (en) 2019-09-26
KR20200144547A (ko) 2020-12-29
IL277464A (en) 2020-11-30
JP2024001136A (ja) 2024-01-09
JP2021519280A (ja) 2021-08-10
WO2019183290A1 (en) 2019-09-26
CN112533940A (zh) 2021-03-19

Similar Documents

Publication Publication Date Title
IL276515A (en) Antibodies specific to PD-L1 and methods of using them
HK1254743A1 (zh) 新穎抗密封蛋白抗體及使用方法
IL268140A (en) Antibodies that help with clotting
EP3250610A4 (en) Fcrn antibodies and methods of use thereof
IL268731A (en) New uses of anti-SIRPG antibodies
EP3280440A4 (en) Humanized anti-c1s antibodies and methods of use thereof
ZA201808524B (en) Methods of affecting separation
EP3288587A4 (en) Modulation of immune response using btla agonist antibodies
EP3204414A4 (en) Novel anti-nodal antibodies and methods of using same
EP3313993A4 (en) ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
GB201603742D0 (en) Source separation method
GB201821206D0 (en) Analytical methods
EP3092002A4 (en) Method of purifying monoclonal antibodies
IL277464A (en) Separation of VWF and VWF propeptide using chromatographic methods
EP3334522A4 (en) ADSORPTION AGENTS AND METHOD FOR THE PRODUCTION AND USE OF ADSORPTION AGENTS
IL258515A (en) Treatment methods using anti-il-17a/f antibodies
EP3356418A4 (en) ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USE
EP3365367A4 (en) MONOCLONAL ANTIBODIES TO BED TAILS AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB201617628D0 (en) Method of determining presence of Isotopes
HUE048056T2 (hu) Eljárás a guayul izoprén alkotóelemeinek elválasztására
GB201704115D0 (en) Method of selecting for antibodies
GB201712166D0 (en) Methods for immuno chromatographic assay desensitization
ZA201900930B (en) Chromatographic separation of mo-99 from w-187
GB201801312D0 (en) Analytical methods
ZA201505095B (en) Antibody fragments specific to von willebrand factor propeptide (vwfpp)